Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

- Conference call webcast Monday, 5:00 p.m. EDT and Tuesday, 7:00 a.m. Australian EST at http://www.antisense.com.au and http://www.isispharm.com

MELBOURNE, Australia and CARLSBAD, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Antisense Therapeutics Ltd. (ASX: ANP) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) are pleased to advise that the results from the ATL/TV1102 Phase IIa clinical trial in patients with multiple sclerosis (MS) were presented Saturday at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada by the Principal Investigator for the trial, Volker Limmroth, M.D., Ph.D., Chairman of the Department of Neurology, Cologne City Hospitals, Germany.

As previously reported, ATL/TV1102 significantly reduced disease activity in patients with Relapsing Remitting Multiple Sclerosis (RRMS) in a randomized, double-blind, placebo-controlled Phase II study designed to obtain evidence of ATL/TV1102's effectiveness in reducing MS-related brain lesions as detected by magnetic resonance images (MRI). The study met its primary endpoint showing a significant reduction by 54.4% (p=0.01) in cumulative number of new active lesions in the ATL/TV1102 treated patients compared to placebo. Further details on the study design and outcomes are provided in the conference abstract which follows this document.

Dr. Limmroth said, "As VLA-4 is a clinically validated target in MS, there is high interest in the potential application of treatment modalities directed against this target. In our study we were able to demonstrate, for the first time, that a second-generation antisense drug designed to speci
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... -- Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, announced today that ... Technology Growth Capital, Inc. (NYSE: HTGC ) ... under the Loan and Security Agreement that Alimera,s subsidiary ... Sciences Limited, entered into with Hercules in April of ...
(Date:9/30/2014)... 2014 The Chinese wound care market is ... in the incidence of lifestyle diseases, coupled with the ... of better quality of wound care products provide the ... of public health insurance schemes and increased reimbursement rate ... on the findings of primary and secondary researches, this ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2China Wound Care Market 2China Wound Care Market 3
... HAYWARD, Calif., Feb. 1, 2011 Anthera Pharmaceuticals, Inc. ... drugs to treat serious diseases associated with abnormal auto-immune ... Dr. Peter Thompson to its Board of Directors. Currently, ... is the founder and Managing Director of Strategicon Partners, ...
... Mich., Feb. 1, 2011 Stryker Corporation (NYSE: ... previously announced sale of its OP-1 product family, which ... use in orthopaedic bone applications. The transaction also includes ... Stryker is one of the world,s ...
Cached Medicine Technology:Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors 2
(Date:10/1/2014)... Raleigh, NC (PRWEB) October 01, 2014 ... combination of three drugs that target immune system proteins ... Surviving Mesothelioma has just posted details of the new ... the story now. , Researchers in the UWA ... TGF-ß, and anti-CTLA-4 drugs to mice with mesothelioma with ...
(Date:10/1/2014)... at the occasion of the Leishmaniasis East Africa ... and international leishmaniasis experts, results of a pharmacovigilance ... plan, carried out by MSF, DNDi, and ... were presented to key decision makers in order ... with the combination of Sodium Stibogluconate and Paromomycin ...
(Date:10/1/2014)... October is national Breast Cancer Awareness ... plans while raising money for breast cancer research. Pelican ... Month in the effort to find a cure. ... importance of having access to clean, healthy water. Research ... to certain forms of cancer. , The Problem ...
(Date:10/1/2014)... Dr. Saj Jivraj, one of the world’s ... to Chennai, India, tomorrow to speak at the Indian ... , Dr. Jivraj is founder of the Anacapa Dental ... one of the world’s foremost prosthodontists, meaning he is ... speaking to the Indian Society of Oral Implantologists about ...
(Date:10/1/2014)... WA (PRWEB) October 01, 2014 Two ... will take them across the country in an effort ... today’s military families. The cyclists, a father-daughter team, ... states, beginning in Blaine, Washington and finishing in Key ... benefit Hope For The Warriors®, a national nonprofit organization ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
... than cancer itself. A patient may respond to one ... and stop responding to the drug -- resulting in months ... , Now UCLA scientists have tested a non-invasive approach ... response to a drug before prescribing therapy, enabling physicians to ...
... a first-ever procedure, surgeons at Johns Hopkins have successfully ... in the back of the donor,s vagina. , "The ... niece, and both patients are doing fine," says Robert ... Johns Hopkins University School of Medicine who led the ...
... ANDS ) announced today that it will present ... Monday, February 9, 2009 at 11:00 a.m. EST (8:00 a.m. ... Hotel in New York. Steve Worland, Ph.D., President and ... Anadys and an update on its clinical programs: ANA598 ...
... 2 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... conference call with simultaneous webcast on Tuesday, February 3, ... Members of Rigel,s senior management team will provide an ... Call and Webcast Information To access the live call, ...
... to Capture and Automate Faxes to Enhance Productivity and Facilitate Regulatory ... ... -- FaxBack® , the high-density VoIP fax leader for Enterprise, ... Integration Server , an easy-to-install plug-in that turns fax machines into ...
... First Quarter EPS and Adjusted EPS Despite a Challenging Economic ... the Company) (Nasdaq: HOLX ), a leading developer, ... surgical products dedicated to serving the healthcare needs of women, ... 2008. Highlights of the quarter include: ...
Cached Medicine News:Health News:UCLA scientists develop crystal ball for personalized cancer treatment 2Health News:Hopkins transplant surgeons remove healthy kidney through donor's vagina 2Health News:Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference 2Health News:Rigel to Host Conference Call on February 3, 2009 2Health News:FaxBack Enables Fax Machine Integration With Document Management Systems 2Health News:FaxBack Enables Fax Machine Integration With Document Management Systems 3Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 2Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 3Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 4Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 5Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 6Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 7Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 8Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 9Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 10Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 11Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 12Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 13Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 14Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 15Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 16Health News:Hologic Announces First Quarter Fiscal 2009 Operating Results 17
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: